Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2742-2747

  Hande, Kenneth ^a,b   Messenger, Mark ^a   Wagner, Judy ^c   Krozely, Mary ^a   Kaul, Sanjeev ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE DILUTION ASSAY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DEUTERIUM; ETOPOSIDE; HUMANS; INJECTIONS, INTRAVENOUS;

EID: 0032697303     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kobayashi, K., Jodrell, D. I., and Ratain, M. J. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring Cancer Surveys, 17: 51-78, 1993.
2. Galpin, A. J., and Evans, W. E. Therapeutic drug monitoring in cancer management. Clin. Chem., 39: 2419-2430, 1993.
3. Ratain, M. J., Mick, R., Schilsky, R. L., Vogelzang, N. J., and Berezin, F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol., 9: 1480-1486, 1991.
4. Stewart, C. F., Arbuck, S. G., Fleming, R. A., and Evans, W. E. Relationship of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther., 50: 385-393, 1991.
5. Joel, S. P., Shah, R., Clark, P. T., and Slevin, M. L. Predicting etoposide toxicity: relationship to organ function and protein binding. J. Clin. Oncol., 14: 257-267, 1996.
6. McLeod, H. L., and Evans, W. E. Clinical pharmacokinetics and pharmacodynainics of epipodophyllotoxins. Cancer Surveys, 17: 253-267, 1993.
7. Smith, R. D., Pfeffer, M., Scalzo, A., and Comis, R. L. Bioavailability and pharmacokinetics of etoposide. Semin. Oncol., 12 (Suppl.): 48-51, 1985.
8. Hande, K. R., Krozely, M. G., Greco, F. A., Hainsworth, J. D., and Johnson, D. H. Bioavailability of low-dose etoposide. J. Clin. Oncol., 11: 374-377, 1993.
9. Joel, S. P., Clark, P. I., Heap, L., Webster, L., Robbins, S., Craft, H., and Slevin, M. L. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother. Pharmacol., 37: 125-133, 1995.
10. Fujiwara, Y., Ohune, T., Okusaki, K., Niitani, K., Sumiyoshi, H., Taakemoto, Y., Yamaoka, N., and Yamkido, M. Bioavailability of 50 and 75 mg oral etoposide in lung cancer patients. Cancer Chemother. Pharmacol., 37: 327-331, 1996.
11. Ratain, M. J. Pharmacokinetics and pharmacodynamics. In: V. T. DeVita, S. Hellman, and S.A. Rosenberg (eds.). Cancer: Principles and Practice of Oncology, Ed. 5, pp. 375-385. Philadelphia, PA: Lippincott-Raven, 1997.
12. Gibaldi, M., and Perrier, D. Pharmacokinetics, Ed. 2, pp. 1-9C. New York, NY, Marcel Dekker, 1982.
13. Hande, K. R., Wedland, P. J., Noone, R. M., Wilkinson, G. R., Greco, F. A., and Wolff, S. N. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res., 44: 379-382, 1984.
14. Newman, E. M., Doroshow, J. H., Forman, S. J., and Blume, K. G. Pharmacokinetics of high-dose etoposide. Clin. Pharmacol. Ther., 43: 561-564, 1988.
15. Devlin, R., Cohen, A., Funke, P., and Stern, M. Stable isotopes in bioequivalence testing. Clin. Pharmacol. Ther., 31: 217-218, 1982.
16. DeMario, M. D., and Ratain, M. J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol., 16: 2557-2567, 1998.
17. Creaven, P. J., and Allen, L. M. EPEG, a new antineoplastic epipodophyllotoxin. Clin. Pharmacol. Ther., 10: 221-226, 1975.
18. D'Incalci, M., Farina, P., Sessa, C., Mangioni, C., Conter, V., Masera, G., Rocchetti, M., Pisoni, M. B., Piazza, E., Beer, M., and Cavalli, F. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother. Pharmacol., 7: 141-145, 1982.
19. Stewart, D. J., Nundy, D., Maroun, J. A., Tetreault, L., and Prior, J. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat. Rep., 69: 269-273, 1985.
20. Arbuck, S. G., Douglas, H. O., Crom, W. R., Goodwin, P., Silk, Y., Cooper, C., and Evans, W. E. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J. Clin. Oncol., 4: 1690-1695, 1986.
21. Bennett, C. L., Sinkule, J. A., Schilsky, R. L., Senekjian, E., and Choi, K. E. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res., 47: 1952-1956, 1987.
22. Lowis, S. P., Pearson, A. D. J., Newell, D. R., and Cole, M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res., 53: 4881-4889, 1993.
23. Zucchetti, M., Pagani, O., Torri, V., Sessa, C., D'Incalci, M., DeFusco, M., deJong, J., Gentilli, D., Martinelli, G., Tinazzi, A., and Cavalli, F. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. Clin. Cancer Res., 1: 1517-1524, 1995.
24. Millward, M. J., Newll, D. R., Yuen, K., Matthews, J. P., Balmano, K., Charlton, C. J., Gumbrell, L., Lind, M. J., Chapman, F., Proctor, M., Simmonds, D., Cantwell, B. M. J., and Calvert, A. H. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother. Pharmacol., 37: 161-167, 1995.
25. deJong, R. S., Mulder, N. H., Uges, D. R. A., Kaul, S., Winograd, B., Sleijifer, D. T., Groen, H. M. J., Willemse, P. H. B., vanderGraaf, W. T. A., and deVries, E. G. E. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br. J. Cancer, 75: 1660-1666, 1997.
26. Harvey, V. J., Slevin, M. L., Joel, S. P., Smythe, M. M., Johnston, A., and Wrigley, P. F. M. Variable bioavailability following repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol., 21: 1315-1319, 1985.
27. Campbell, M. A., Perrier, D. G., Dorr, R. T., Alberts, D. A., and Finley, P. R. Methotrexate: bioavailability and pharmacokinetics. Cancer Treat. Rep., 69: 833-838, 1985.
28. Ogouey, D., Kolliker, F., Gerber, N. J., and Reichen, J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum., 35: 611-614, 1992.
29. Zimm, S., Collins, J. M., Riccardi, R., O'Neill, D., Narang, P. K., Chabner, B., and Poplack, D. G. Variable bioavailability of oral 6-mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N. Engl. J. Med., 308: 1005-1009, 1983.
30. Juma, F. D., Rogers, H. J., and Trounce, J. R. Pharmacokinetics, of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol., 8: 209-217, 1979.
31. Struck, R. F., Alberts, D. S., Horne, K., Phillips, J. G., Peng, Y. M., and Roe, D. J. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized cross-over trial. Cancer Res., 47: 2733-2726, 1987.
32. Hande, K. R. Etoposide pharmacology. Semin. Oncol., 19 (Suppl.): 3-9, 1992.
33. Hande, K. R., Anthony, L., Hamilton, R., Sweetman, B., and Branch, R. Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res., 48: 1829-1834, 1988.
34. Relling, M. V., Nemec, J., Schuetz, E. G., Schuetz, J. D., Gonzalez, F. J., and Korzekwa, K. R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol., 45: 352-358, 1994.
35. Leu, B. L., and Huang, J. D. Inhibition of intestinal p-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol., 35: 432-436, 1995.